Cancer Education and Research Institute
Worldwide Access to High-Quality Care, Research, and Education

United Nations, UNIATF Award 2019 Recipient

DONATE to support our programs
  • Home
    • About us >
      • About the Founder
    • Annual Reports and Media Kit
    • News Room >
      • CERI Press Releases 2022
      • CERI Press Releases 2021
      • Press Releases 2020
      • Press Releases 2019
      • Press Releases 2018
      • Press Releases 2017
      • Press Releases 2016
      • Press Releases 2015
      • Press Releases 2014
      • Press Releases 2013
    • Testimonials
  • MULTI-LANGUAGE CANCER BLOG
  • For Patients
    • CERI Personalized Patient Program™
    • All about cancer
    • Cancer Education
    • Watch Our Cancer Videos >
      • Ovarian cancer diagnosis
    • Our Publications >
      • Read CERI Simplified Cancer Research Articles
    • Cancer Types
    • Cancer detection and cancer treatment
    • Cancer Awareness Months
  • Events
  • Donate
    • Sponsorship levels
    • Membership
    • Become A Sponsor
    • Shop at CERI
    • Volunteer
    • Become a CERI Board Member
  • Contact us

Phase 2 study results for Chronic Lymphocytic Leukemia (CLL) patients

6/17/2019

0 Comments

 
Tweet
Combining venetoclax (Veneclexta) + ibrutinib (Imbruvica) may be an effective initial treatment for previously untreated patients with CLL (a.k.a Chronic Lymphoblastic Leukemia), ​results of a Phase II (Phase 2) study by The University of Texas MD Anderson Cancer Center, published on May 29, 2019, suggest.
Both of these drugs are already FDA approved. The study was conducted with 80 previously untreated patients.
  • Median age was 65 years with 30 percent over age 70.
  • Of these patients, 92% had high-risk genetic anomalies.
  • 88% of patients had complete remission with normal or incomplete blood count recovery after 12 cycles of treatment.
  • 61% of patients had complete remission with undetectable minimal residual disease.
  • 60% of patients developed low white blood cell counts, similar to what has been reported in other venetoclax combination trials.
​
According to the researchers, the combination of these two drugs gave substantially better results than each of these two drugs alone. 

The researchers also added that more robust therapies for CLL patients are needed, due to the fact that:
  1. majority of patients are older than 65, and
  2. that the existing therapies are not always effective.

One of the lead researchers, Dr. Jain, said the following: “This group of patients often has unacceptable side effects and has a lower rate of complete remission and undetectable minimal residual disease. Our data showed that non-chemotherapy, combination therapy with ibrutinib and venetoclax demonstrated no new toxic effects compared to what has been previously reported for the individual agents.”

No new safety concerns were observed with the combination therapy.

The current median follow-up of the trial is 14.8 months. However, according to the researchers a longer follow-up is needed to adequately assess the long-term safety of this combination.

Study findings were published in New England Journal of Medicine on May 29, 2019.

Lead researchers of the study included:
  • Nitin Jain, M.D., Associate Professor of Leukemia 
  • William Wierda, M.D., Ph.D., Professor of Leukemia
  • Varsha Gandhi, Ph.D., Department Chair ad interim of Experimental Therapeutics
Phase II study results for Chronic Lymphocytic Leukemia (CLL) patients - Cancer Education and Research Institute (CERI)
References: 
  1. ​Study reports ibrutinib and venetoclax combo effective as front-line therapy for select chronic lymphocytic leukemia patients. 
  2. Ibrutinib and Venetoclax for First-Line Treatment of CLL, Nitin Jain, M.D., Michael Keating, M.D., Philip Thompson, M.D., et al., N Engl J Med 2019; 380:2095-2103.

#ChronicLymphocyticLeukemia #CLL #ChronicLymphoblasticLeukemia #clinicaltrials #mdanderson #mdandersoncancercenter #leukemia #cancertreatment #venetoclax #Veneclexta #ibrutinib #Imbruvica
0 Comments

BREAKING NEWS-Gene identified necessary for pancreatic cancer development

5/3/2019

0 Comments

 
Gene identified necessary for pancreatic cancer development!
Researchers from New York University and University of Michigan have identified a gene called Atdc (ataxia-telangiectasiagroup D-complementing) that is necessary for pancreatic cancer development. 

Pancreatic ductaladenocarcinoma (PDA) is an aggressive form of pancreatic cancer that is driven by the oncogenic (cancer causing) KRAS. It is diagnosed in late stages and is resistant to therapy. 

“We thought the deletion [
of the Atdc gene] would slow cancer growth, not completely prevent it,” said Diane Simeone, director of the Pancreatic Cancer Center of NYU LangoneHealth’s PerlmutterCancer Center, and corresponding author of the study. 
BREAKING NEWS-Gene identified necessary for pancreatic cancer development - Cancer Education and Research Institute (CERI)
The researchers have shown that deletion of the ataxia-telangiectasia group D-complementing (Atdc) gene, which is up-regulated (found in multiple copies) in the majority of pancreatic adenocarcinoma, completely prevented PDA development in the context of oncogenic KRAS. When the Atdc gene was present, 100% of the mice with KRAS and other mutations (gene abnormalities) developed PDA.  Mice lacking ATDC are protected from developing PDA.

As for the mechanism, the researchers showed that ATDC promotes acinar–ductal metaplasia (ADM) to pancreatic intraepithelial neoplasia (PanIN) through the activation of β-catenin signaling and subsequent SOX9 up-regulation (over expression). 

This breakthrough study revealed great hope for the development of potential new therapies for pancreatic cancer. 
The study has been published today, May 2, 2019 in the scientific journal Genes & Development.

Corresponding author of this study is Dr. Diane Simeone: diane.simeone@nyulangone.org

#breakingnews #breakthrough #science #sciencenews #cancerresearch #pancreaticcancer #cancer #cancerresearch #genes #newyorkuni #nyulangone #umich #umichigan #newyork #michigan #langone #hope #pancreaticcancerawareness
0 Comments

Drinking when young increases breast cancer risk study reports

10/3/2018

0 Comments

 
Tweet
Young women who regularly drink alcohol before their first pregnancy may be increasing their risk for breast cancer study published in The Journal of the National Cancer Institute reports. The study says that the "breast tissue is particularly susceptible to carcinogens between menarche and first full-term pregnancy". 

This report is the conclusion of a 20-year study, summerizing data from 91,005 parous women. 

The report concludes that "Alcohol consumption before first pregnancy was consistently associated with increased risks of proliferative benign breast disease (BBD) and breast cancer."

Drinking when young increases breast cancer risk - cancer education and research institute
References: 
  1. J Natl Cancer Inst;2013;105:1571–1578
  2. The New York Times, 9/6/2013. 
#breastcancer #driking #womendrinking #breastcancerrisk #cancerrisk #drinkingandcancerrisk #drinkingandbreastcancerrisk #alcohol #effectsofalcohol #health #cancer #breastcancerawareness #cancerawreness #breastcancerawarenessmonth #BCAM #cancerprevention #cancereducation #canceredinstitute 
0 Comments

Engineered “shared” immune cells led to remission in childhood leukemia

1/28/2017

0 Comments

 
Tweet
Picture
Read the scientific article entitled Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells here.

To learn more about Acute Lymphoblastic Leukemia (ALL), read our article here.   

​#leukemia #ALL #AcuteLymphoblasticLeukemia #CAR #CARTCells #immunesystem #geneengineering #TALEN #Crispr #geneediting #universalTcells #universalimmunecells #childhoodleukemia #cchildhoodcancer #universitycollegelondon #cancerresearch #cancertreatment #cancer #cancereducation #patientenducation #publiceducation #canceredintitute 
0 Comments

Capsaicin in chillies kills breast cancer cells

1/3/2017

0 Comments

 
Tweet
Capsaicin in chillies kills breast cancer cells - Cancer Education and Research Institute (CERI)
Researchers from Ruhr-University in Bochum, Germany, treated human samples of breast cancer cells with Capsaicin to dissect its ability to destroy them. They found that Capsaicin induces apoptosis (cell death) in cancer cells. When capsaicin reaches a cancer cell, it attaches to the cell surface and switches on a cell receptor, a protein expressed/produced on the cell surface, called TRPV1. The receptor TRPV1 is a calcium/sodium channel that controls them go in and out of the cancer cell. When TRPV1 is switched on by capsaicin, the cancer cell is sent into overdrive and starts to self-destruct by induced apoptosis (programmed cell death). The researchers have found a significant reduction in cell proliferation after capsaicin stimulation was observed.This study was carried out by scientists from:
  • Ruhr-University in Bochum, Germany
  • Hospital Herz-Jesu-Krankenhaus Dernbach, Germany
  • Centre of Genomics in Cologne, Germany

Read more here in the news, and the original scientific article, Expression and functionality of TRPV1 in breast cancer cells, here.


0 Comments

Light therapy effective in treating early-stage prostate cancer

12/22/2016

0 Comments

 
Tweet
University College London Hospitals (UCLH) researchers used a light-sensitive drug, which is injected into the bloodstream. A laser then activates the drug, which eradicates tumor tissue in the prostate. This new treatment is called vascular-targeted photodynamic therapy, or VTP. 
Vascular-treated photodynamic therapy - VTP - prostate cancer - Cancer Education and Research Institute (CERI)
Published in The Lancet Oncology, the study showed that 49 percent of patients given VTP went into ‘complete remission’ compared with 13.5 percent of patients in the control group.

The scientific title of the study is called 'Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial'

Read more on CNBC's website:
www.cnbc.com/2016/12/20/a-new-form-of-therapy-involving-lasers-could-transform-the-way-prostate-cancer-is-treated.html

Read the scientific article on The Lancet Oncology's website:
www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30661-1/fulltext

0 Comments

FDA approves new treatment for advanced ovarian cancer

12/19/2016

0 Comments

 
Tweet
​FDA approves today Rubraca (rucaparib) to treat women with advanced ovarian cancer that has BRCA gene mutation. 
FDA approves new treatment for advanced ovarian cancer - Cancer Education and Research Institute (CERI)
BRCA genes are involved with repairing damaged DNA. Thus, under normal conditions, they work to prevent tumor development. However, mutations (abnormalities) of these genes may lead to certain cancers, which include breast and ovarian cancers. Rubraca is a poly ADP-ribose polymerase (PARP) inhibitor that blocks an enzyme (a protein involved in catalytic reactions in our body), which is involved in repairing damaged DNA. By blocking this enzyme through Rubraca, DNA inside the cancerous cells with damaged/mutated/abnormal BRCA genes may be less likely to be repaired by the enzyme, which leads to cell death and potentially a slow-down or inhibition of tumor growth.

Common side effects of Rubraca include nausea, fatigue, vomiting, low levels of red blood cells (anemia), abdominal pain, unusual taste sensation (dysgeusia), constipation, decreased appetite, diarrhea, low levels of blood platelets (thrombocytopenia) and trouble breathing (dyspnea).  Rubraca is associated with serious risks, such as bone marrow problems (myelodysplastic syndrome), a type of cancer of the blood called acute myeloid leukemia and fetal harm.


Rubraca is marketed by Clovis Oncology, Inc. based in Boulder, Colorado. The FoundationFocus CDxBRCA companion diagnostic is marketed by Foundation Medicine, Inc. of Cambridge, Massachusetts.

For more information visit the FDA's website: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm533873.htm

0 Comments

Skin cancer test offered at Rhode Island beaches #skincancer #news #rhodeisland #beach #cancer 

7/7/2014

0 Comments

 
Source: http://www.sfgate.com/news/article/Skin-cancer-test-offered-at-Rhode-Island-beaches-5602911.php

PROVIDENCE, R.I. (AP) — Beachgoers can get a free skin cancer screening at Rhode Island beaches in July and August.

The Rhode Island Department of Health, the Comprehensive Cancer Center at Rhode Island Hospital and U.S. Sen. Jack Reed, D-Rhode Island, will launch the Sun Smarts Sunscreen Campaign Monday at Scarborough Beach in Narragansett, Rhode Island.

Screenings will be offered from 12:30 p.m. to 2:30 p.m. on Fridays: July 11 at Easton's Beach in Newport; July 18 at Roger Wheeler State Beach in Narragansett; Aug. 15 at East Matunuck State Beach in South Kingstown; and Aug. 22 at Sachuest Town Beach in Middletown; and from 12:30 p.m. to 2:30 p.m. on Sunday, July 27 at Scarborough State Beach in Narragansett.

Dermatologists and dermatology residents affiliated with Lifespan Hospital will perform the screenings.

0 Comments

Does CVS "really care" about lung cancer or rather the boost of its  reputation and stock? And is a sales stop enough to reduce the number of smokers to prevent lung cancer? 

2/5/2014

0 Comments

 
CVS announced today to stop selling cigarets. Read the news from several sources here:

http://www.npr.org/blogs/thetwo-way/2014/02/05/271906167/cvs-to-stop-selling-tobacco-products
http://www.cnn.com/2014/02/05/health/cvs-cigarettes/http://abcnews.go.com/Health/wireStory/cvs-caremark-plans-stop-selling-tobacco-products-22371836

Is a stop of selling tobacco cigarets enough for lung cancer prevention? Wouldn't be education more effective, and something we'd need more? 

And here is an interesting statement: "CVS Caremark's stock price was down 55 cents, or a little less than 1 percent, to $65.56 in midday trading." Read more here:
http://www.npr.org/blogs/health/2014/02/05/271997564/by-dropping-cigarettes-cvs-gives-its-reputation-a-boost

What are YOUR thoughts?  Comment below.
0 Comments

Today is World Cancer Day!

2/4/2014

0 Comments

 
World Cancer Day was created to raise awareness worldwide about cancer, and encouraging governments to make cancer research, prevention, and treatment a priority. And, of course, as Cancer Research Simplified, we 100% support this mission. 

You can be a part of this mission too. Here is how you and your loved ones can get involved: 

- Get involved with Cancer Research Simplified and donate for cancer education to prevent and cure cancer,
- Volunteer with us in your community and be an Advocate for our Cause
- Become a Sponsor
- Become a volunteer, intern, or a board member
- Join us on Facebook and other social media platforms, and spread the word about the World Cancer Day, and the need of cancer education and our programs 
0 Comments
<<Previous

    Archives

    January 2023
    December 2022
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    May 2020
    April 2020
    March 2020
    September 2019
    June 2019
    May 2019
    October 2018
    February 2017
    January 2017
    December 2016
    November 2016
    September 2016
    June 2016
    May 2016
    April 2016
    March 2016
    January 2016
    December 2015
    November 2015
    October 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013

    Categories

    All
    Cancer News
    Cancer News
    Cancer Research Simplified News
    Crs News
    Crs News
    Holidays
    Quotes

Yes, I'd like to help CERI continue saving lives!

Make a Monthly Contribution

Cancer Education and Research Institute® (formerly Cancer Research Simplified) is an independent 501(c)(3) non-profit organization.
Homepage 
Türkçe
Deutsch

About us
Meet the Founder
Meet the Team

News Room
Media Kit
Press Releases 
Watch Cancer Videos
Kanser videolarını izle
Krebs Videos ansehen
Cancer Resources

CERI Youth Program

Events

Shop at CERI


Ways to Help
Donate
Volunteer
Become A Sponsor

Blog
Blog-Deutsch
Blog-Türkçe
Blog-Afrikaans
Blog-Espanol
Blog-Italiano
Blog-Russkij
Blog-Portugues


Cancer Awareness Months



Stay Involved
Facebook
Twitter
Youtube
LinkedIn

Testimonials

Jobs

Contact Us
Cancer Research Simplified Homepage
Terms of Service
Privacy Policy
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Copyright © 2013-2023 Cancer Education and Research Institute®. All Rights Reserved. 
Sitemizdeki yazı, video ve resim her hakkı saklıdır. İzinsiz, kaynak gösterilmeden kullanılamaz.  
Alle Rechte vorbehalten.                             

Powered by Cancer Education and Research Institute®